Dr. Cuglievan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe blvd.
Houston, TX 77030
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2015 - 2018
- Nicklaus Children's HospitalResidency, Pediatrics, 2012 - 2015
- University of San Martin de Porres Faculty of MedicineClass of 2010
- Harvard Medical SchoolCertification, Pediatrics , 2009 - 2009
- Markham CollegeIB, 2001
Certifications & Licensure
- FL State Medical License 2015 - Present
- AZ State Medical License 2024 - 2026
- TN State Medical License 2024 - 2026
- WA State Medical License 2024 - 2026
- GA State Medical License 2024 - 2025
- LA State Medical License 2024 - 2025
- MS State Medical License 2024 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- Join now to see all
Awards, Honors, & Recognition
- The President's Award for Research Excellence MD Anderson Cancer Center, 2022
- Excellence in Education MD Anderson Cancer Center, 2020
- Men of Distinction Award 2020
- Join now to see all
Clinical Trials
- Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population Start of enrollment: 2021 Sep 07
- Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL Start of enrollment: 2023 Apr 06
- Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Start of enrollment: 2021 May 21
Publications & Presentations
PubMed
- 34 citationsPredictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.Ghayas C. Issa, Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak
Blood Cancer Journal. 2021-09-29 - 6 citationsLong-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.Amy M Berkman, Clark R Andersen, Branko Cuglievan, David C McCall, Philip J Lupo
Cancer Epidemiology, Biomarkers & Prevention. 2022-06-01 - 16 citationsCyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-reg...Sofia Garces, L Jeffrey Medeiros, Mario Luiz Marques-Piubelli, Sheila Aparecida Coelho Siqueira, Roberto N Miranda
Human Pathology. 2022-03-01
Abstracts/Posters
- Preclinical Efficacy of Targeting EWSR1 In Ewing Sarcoma and Desmoplastic Small Round Cell Tumors.Menegaz BA, Lamhamedi-Cherradi SE, Cuglievan B, Kim Y, Macleod R, Hayes-Jordan A, Ludwig JA, CTOS (Connective Tissue Oncology Society), Rome, 1/1/2018
- Preclinical Efficacy of Androgen Receptor-Based Anti-Sense Therapy for the Treatment of Desmoplastic Small Round Cell Tumor.Menegaz BA, Lamhamedi-Cherradi SE, Cuglievan B, Camacho P, Kim Y, Macleod R, Hayes-Jordan A, Ludwig JA, CTOS (Connective Tissue Oncology Society), Rome, 1/1/2018
- Igf-1r/Mtor Targeted Therapy For Ewing Sarcoma: A Meta-Analysis Of Five Igf-1r-Related Trials Matched To Proteomic And Radiologic Predictive Biomarkers.Amin H, Morani A, Daw N, Lamhamedi-Cherradi S, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin R, Patel S, Song J, Lazar A, Wang W, Kurzrock R, P..., CTOS (Connective Tissue Oncology Society), Rome, 1/1/2018
- Join now to see all
Press Mentions
- Young Acute Lymphoblastic Leukemia Survivor Benefits from Childhood Cancer ProgramsSeptember 12th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: